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Abstract
Recent behavioral reports suggest that repeated exposure to cannabis and synthetic cannabinoid
agonists is linked with mental disorders associated with dysfunction of serotonin 2A (5-HT2A)
receptor neurotransmission such as anxiety and depression. Here, we studied the effect of a
nonselective cannabinoid agonist, CP55940, on the activity of 5-HT2A receptors in hypothalamic
paraventricular nucleus (PVN). We detected that repeated exposure to CP55940 enhanced the
prolactin and corticosterone neuroendocrine responses mediated by 5-HT2A receptors and
increased the membrane-associated levels of 5-HT2A receptors in PVN. Importantly, we also
detected increased anxiety-like behaviors in CP55940 treated rats compared to controls. The data
presented here suggest that the mechanisms mediating the cannabinoid-induced upregulation of 5-
HT2A receptors would be brain-region specific, as we were unable to detect a CP55940-induced
upregulation of 5-HT2A mRNA. Our results might provide insight into the molecular mechanism
by which repeated exposure to cannabinoids could be associated with the pathophysiology of
neuropsychiatric disorders.
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1. Introduction
A number of recent behavioral studies suggest that administration of Δ9-
Tetrahydrocannabiniol (Δ9-THC), the main psychoactive component of marijuana, or
several synthetic cannabinoids can regulate the activity of serotonin 2A (5-HT2A) receptors
[11;24]. While acute cannabinoid administration reduces 5-HT2A receptor-mediated
behavioral responses [11]; repeated exposure to cannabinoids seems to be associated with
increased behavioral responses to 5-HT2A receptor agonists in adult rats [24]. Accordingly,
we have recently reported that repeated exposure to cannabinoid agonists upregulates and
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increases the activity of 5-HT2A receptors in rat prefrontal cortex (PFCx) and in two
neuronal cell models [17–20].
Cannabinoids produce their responses by activating two cannabinoid receptors, CB1 and
CB2 receptors, in the brain [8]. These receptors are expressed in different areas of the brain,
including PVN, amygdala, cerebellum, hippocampus, and cortex [1;2;13;16;22]. CB1 and
CB2 receptors couple to Gi/o class of G-proteins and to the extracellular kinase (ERK)
signaling pathway [4;8]. In our previous studies, we have reported that the cannabinoid-
induced upregulation of 5-HT2A receptors in two neuronal cell models is mediated by CB2
receptors and ERK1/2 activation as it is inhibited in cells treated with CB2, but not CB1,
shRNA lentiviral particles and by ERK1/2 inhibitors [17–19].
Activity of 5-HT2A receptors in either PFCx or hypothalamic paraventricular nucleus (PVN)
has been associated with several physiological functions and neuropsychiatric disorders such
as stress response, anxiety & depression and schizophrenia [6;12]. Although the clinical
manifestations of the cannabinoid -induced upregulation of 5-HT2A receptors are currently
under discussion, it has been suggested that repeated exposure to nonselective cannabinoid
agonists might fasten the onset of the neuropsychiatric disorders described above
[6;23;26;27;34]. Of note, recent preclinical studies indicated that chronic, but not acute,
exposure to non-selective [30;31] or selective CB2 receptor agonists induced anxiety-like
behaviors in rodents [21].
Here, we investigated the effect of repeated exposure to CP55940 on the activity of 5-HT2A
receptors in the hypothalamic PVN. CP55940 is a nonselective cannabinoid agonist (CB1
and CB2 agonist, Ki: 0.58 nM and 0.68 nM for CB1 and CB2 receptors, respectively) [35].
We measured [(−)-1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane HCl] (−)DOI, 5-
HT2A/AC agonist, induced changes in neuroendocrine responses, corticosterone and
prolactin plasma levels, as an index of activity of 5-HT2A receptors in PVN. We have
previously demonstrated that the neuroendocrine effects of (−)DOI are mediated exclusively
by activation of 5-HT2A receptors, but not 5-HT2C receptors, in rat PVN [39;41]. Here we
reported a cannabinoid agonist-induced upregulation of 5-HT2A receptors in hypothalamic
PVN and increased-anxiety like responses in rats treated with CP55940. We hypothesize
that these studies will further our understanding of the neurobiological mechanisms
associated with repeated cannabinoid exposure.
2. MATERIALS AND METHODS
2.1 Drugs
CP55940, a CB1/CB2 agonist, was purchased from Tocris (Ellisville, MO). A fresh
CP55940 solution (0.05 mg/ml) was prepared in Tween-80/ethanol/saline (1:1:18) prior to
each dosing. (−) DOI [(−)-1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane HCl] was
purchased from Sigma-Aldrich Inc. (St. Louis, MO) and dissolved in 0.9% saline at one
concentration (0.35 mg/kg, s.c.). All solutions were made fresh before administration and
injected at a volume of 1 ml/kg.
2.2 Animal Experimental Protocol
Male Sprague-Dawley rats (225–275 g) were purchased from Harlan (Indianapolis, IN). The
rats were housed two per cage in a temperature-, humidity-, and light-controlled room (12
hrs light/dark cycle, lights on 7:00 AM–19:00 PM). Food and water were available ad
libitum. All procedures were conducted in accordance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals as approved by the University of Kansas
Institutional Animal Care and Use Committee (IACUC).
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After arrival, the rats were allowed to acclimate to their environment for at least 7 days prior
to the start of the treatment period. Eight rats were randomly assigned to each group. Cage-
mates were assigned to the same treatment group. Rats were injected with either vehicle
(1ml/kg, i.p.) or CP55940 (0.05 mg/kg, i.p.) once a day for 7 days. Rats were sacrificed by
decapitation 48 hrs after the last CP55940 injection. The rats were challenged with either
saline (1ml/kg) or (−)DOI (0.35 mg/kg) 30 min prior to sacrifice. Trunk blood was collected
for hormone assays and brain tissues were rapidly obtained and frozen in dry ice.
2.3 Radioimmunoassay
Plasma prolactin and corticosterone concentrations were determined by radioimmunoassays
as previously described [7].
2.4 Western blots
Membrane-associated proteins were isolated using the ProteoExtract™ Native Membrane
Protein Extraction kit (Calbiochem, La Jolla, CA) according to manufacturer’s instructions.
Briefly, PVN tissue was homogenized in extraction buffer I containing protease inhibitor
cocktail. Homogenates were incubated for 15 mins at 4°C under gentle agitation, centrifuged
16,000 × g for 15 mins at 4°C, and then the supernatant containing the cytosolic fraction was
collected. The pellet was incubated with extraction buffer II with protease inhibitor cocktail
for 30 mins at 4°C under gentle agitation and centrifuged 16,000 × g for 15 mins at 4°C to
isolate the membrane fraction contained in the supernatant. Expression of membrane-
associated 5-HT2A receptors in PVN was determined by Western blot as previously
described [7]. Films were analyzed densitometrically using Scion Image software (Scion
Corporation, Frederick, MD, USA) as previously described [7]. Each sample was measured
on three independent gels. All samples were standardized to controls and normalized to their
respective actin levels.
2.5 Quantitative Real-Time PCR
These reactions were prepared using QuantiFast SYBR Green PCR Kit (Qiagen, Valencia,
CA), the ABI 7500 fast real time PCR system (Applied Biosystems, Foster City, CA) and
then data was analyzed using the comparative cycle threshold (Ct) method as described [36].




GGCATGGACTGTGGTCATGA-3’). These primers have been previously validated
[3;25;29].
2.6 Behavioral Tests
We used a separate group of rats to measure anxiety-like behaviors in rats injected with
either vehicle (1ml/kg, i.p.) or CP55940 (0.05 mg/kg, i.p.) once a day for 7 days. 48 hrs after
the last CP55940 injection, anxiety-like behaviors and locomotor activity were assessed in
an elevated plus maze (Med Associates,St. Albans,VE) as previously described [32;37].
2.7 Statistics
All data are expressed as the mean ± S.E.M., where n indicates the number of rats per group.
Data was analyzed by an unpaired Student’s t-test or ANOVA (Newman-Keuls post-hoc
test). GB-STAT software (Dynamic Microsystems, Inc., Silver Spring, MD, USA) was used
for statistical analyses.
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We first examined the effect of repeated administration of CP55940, a CB1/CB2 receptor
agonist [4], on the activity and expression of 5-HT2A receptors in PVN. Rats were treated
with CP55940 once a day for 7 days and then were challenged with (−)DOI (5-HT2A/2C
receptor agonist) 30 mins prior to sacrifice. We used this challenge to measure activity of 5-
HT2A receptors in PVN because the neuroendocrine effects of (−)DOI, are mediated
exclusively by activation of 5-HT2A receptors, but not 5-HT2C receptors, in PVN [7]. In
(−)DOI-challenged rats, we found significant (p<0.05) increases in 5-HT2A receptor-
mediated prolactin (Fig.1A) and corticosterone (Fig.1B) plasma levels. The levels of
prolactin increased from 28.1 ± 0.9 pg/ml in control rats challenged with (−)DOI to 44.60 ±
2.2 in CP55940-treated rats challenged with 0.35nM (−)DOI (Fig.1A). Plasma
corticosterone levels increased from 21.5 ± 0.6 in control rats to 35.7 ± 0.7 in CP55940-
treated rats (Fig.1B).
Upregulation of 5-HT2A receptors could mediate this cannabinoid-induced phenomenon in
hypothalamic tissue. Interestingly, we found a significant (p<0.01) increase in the
membrane-associated 5-HT2A receptor protein levels in PVN of rats treated with CP55940
compared to controls (approx. 5-fold increase in PVN, Fig.1C). Increased mRNA synthesis,
decreased receptor degradation, and/or increased translocation of these receptors from the
cytosol to the membrane are the plausible mechanisms that could underlie the increased
membrane-associated levels of 5-HT2A receptors shown in Fig.1C. We then measured 5-
HT2A mRNA levels in PVN samples of either controls or CP55940-treated rats. In PVN, we
did not find any significant CP55940-mediated changes in 5-HT2A mRNA levels (Fig.1D)
nor did we detect any modification in the levels of 5-HT2A receptor-associated G-protein,
Gαq (Fig.1D).
Repeated cannabinoid administration has been linked to increased anxiety, depressed mood,
irritability and restlessness [5;10]. Here we want to determine whether the increased
cannabinoid-induced activity of hypothalamic 5-HT2A receptors is associated with anxiety-
like behaviors in rats. We used a separate group of rats to measure anxiety-like behaviors in
CP55940 treated animals 48 hours after the last cannabinoid administration. In the elevated
plus maze, anxiety-related behavior is measured by the degree to which the rodent avoids
the open (unenclosed) arms of the maze [32]. Since locomotor activity affects the
interpretation of the elevated plus maze observations, we measured the number of transitions
between the different arms of the maze as an index of locomotor activity as previously
described [21].
We detected significant (p<0.05) differences between vehicle and CP55940 treated rats
when we measured the percent time spent in open arms of the plus maze (% open arms/total
time, Fig.2A). Indeed, we detected that vehicle treated rats spent significantly (p<0.05) more
time in the open arms of the maze compared to CP55940-treated rats (28.6 ± 3.2% and 16.4
± 4.8% for vehicle and CP55940-treated rats, respectively). Interestingly, we did not detect
any significant changes in the number of transitions between the different arms of the maze
in vehicle or CP55940-treated rats (31.4 ± 2.9 and 33.0 ± 3.8 for vehicle and CP55940-
treated rats, respectively) (Fig.2B).
4. DISCUSSION
Our results identified a cannabinoid agonist-induced increase of 5-HT2A signaling in the
hypothalamic PVN cells that was manifested by increased prolactin and corticosterone
neuroendocrine responses to (−)DOI, a 5-HT2A/2C receptor agonist (Fig.1A & 1B). We
have demonstrated that the neuroendocrine effects of (−)DOI on the secretion of these two
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stress hormones, are mediated by activation of 5-HT2A receptors in PVN [39;41]. We used
(−)DOI (0.35 mg/kg), a submaximal dose (close to EC50) in these studies, since higher doses
of (−)DOI may reach a ceiling effect that may prevent us from quantifying the cannabinoid-
induced increases in 5-HT2A receptor activity in this brain area, as previously reported [24].
The upregulation of 5-HT2A receptors is a mechanism that could mediate the increased
activity of the 5-HT2A receptor. Indeed, we found increased membrane-associated 5-HT2A
receptor protein levels in PVN of CP55940-treated rats that were not associated with
changes in 5-HT2A mRNA (Fig.1C & 1D). Since 5-HT2A receptors seem to be located
mostly in the cytosol of neuronal cells [14;40], it is possible than repeated cannabinoid
exposure may enhance the translocation of the receptor from the cytosol to the membrane
and/or decrease the degradation of this receptor. Interestingly, we have reported that
repeated exposure to cannabinoids is also associated with increased activity and protein
expression of membrane-associated 5-HT2A receptors in rat PFCx [17;18]. However, this
latter phenomenon was associated with increased 5-HT2A mRNA levels in rat PFCx
suggesting that the mechanism by which CP55940 increase the protein expression and
activity of 5-HT2A receptor in brain might be brain-region specific.
Enhanced activity of 5-HT2A receptors in hypothalamic PVN has been associated with
several mood disorders including anxiety [6;15]. Repeated exposure to cannabinoids has
been linked to increased anxiety, depressed mood, irritability, and restlessness [5;10]. When
we used a separate group of rats to measure the effect of CP55940 on anxiety-like behaviors,
we found that the time CP55940-treated rats spent in the open arms of the elevated plus
maze was reduced compared to vehicle controls. This was not associated with changes in the
number of transitions between vehicle and cannabinoid-treated rats, suggesting that repeated
exposure to CP55940 enhances anxiety-like behaviors in rats without modifying locomotor
activity. These studies are in line with preclinical reports that show chronic exposure to
CP55940 and JWH133 (selective CB2 agonist) induce anxiety-like behaviors in young adult
[21] and adolescent rodents [31], respectively. Noteworthy, clinical studies have reported
that chronic cannabinoid users have higher levels of anxiety compared with control groups
[33]. Furthermore, the severity of anxiety symptoms increased as the level of cannabinoid
use increased [9;28].
Further studies are required to identify the cannabinoid receptor and the specific mechanism
by which CP55940 upregulates 5-HT2A receptors in hypothalamic PVN. Our studies in two
neuronal cell models suggest that CB2, but not CB1, receptors mediate this phenomenon
[17–20]. Importantly, a 2011 report stated that Marijuana use among U.S. high school
students has increased since 2008 [38]. The percentage of high school students who reported
using marijuana or synthetic cannabinoids increased from 32% in 2008 to 39% in 2010 [38].
Despite this high incidence, the mechanism by which cannabinoid exposure produce some
of its adverse effect is unknown. The significance of our studies is that they may be
clinically relevant with respect to facilitating a better understanding of some mechanisms
that may underlie the etiology of neuropsychiatric disorders in individuals repeatedly
exposed to cannabinoids.
5. Conclusions
This study provides new insight into the cannabinoid agonist regulation of 5-HT2A receptors
in rat hypothalamic PVN. Furthermore, to the best of our knowledge this study is the first to
show that repeated CP55940 treatment enhances 5-HT2A receptor mediated increases in the
neuroendocrine responses of two stress hormones, prolactin and corticosterone. We also
detected increases in 5-HT2A activity and protein expression in PVN and increased anxiety-
like behavior in CP55940 treated rats. Therefore, this cannabinoid-induced upregulation of
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5-HT2A receptors might represent a potential adverse effect of long-term exposure to certain
cannabinoid agonists.
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PVN hypothalamic paraventricular nucleus
CP 55,940 (−)-cis-3-[2-Hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-
hydroxypropyl)cyclohexanol
(−)DOI [(−)-1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane HCl]
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• Repeated CP55940 treatment enhances 5-HT2A-mediated neuroendocrine
responses.
• 5-HT2A protein levels in PVN were increased after repeated CP55940 treatment.
• 5-HT2A and Gαq mRNA levels in PVN were not modified by CP55940
treatment.
• CP55940 treatment increases anxiety-like behavior in rats.
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Figure 1. CP55940-induced enhanced activity and upregulation of 5-HT2A receptors in
hypothalamic PVN
(A and B) Increased 5-HT2A receptor-mediated prolactin and corticosterone neuroendocrine
responses in CP55940 and (−)DOI treated rats compared to vehicle and (−)DOI treated
controls. *p<0.05, significant effect of (−)DOI challenge in vehicle or CP55940 treated rats
compared to vehicle-treated controls. #p<0.05, significant effect (−)DOI challenge in
CP55940 treated rats compared to (−)DOI challenge in vehicle-treated rats. (C) Increased
membrane-associated 5-HT2A receptor protein levels in the PVN of rats treated with
CP55940 compared to vehicle treated controls. β-actin was used as a loading control and
similar results were obtained in three separate experiments. (D) No significant changes in 5-
HT2A or Gαq mRNA levels in PVN of CP55940 treated rats compared to vehicle treated
controls. Data represent the mean ± SEM of 8 rats per group and were analyzed by one-way
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ANOVA or t-Student test. *p<0.05, significant effect of CP55940 compared with their
respective vehicle-treated controls.
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Figure 2. Effect of repeated CP55940 treatment on anxiety-like behavior in the elevated plus
maze test
(A) Percent time spent in the open arms of the elevated plus maze was reported as a measure
of anxiety-like behavior which was evaluated for a period of 5 minutes. (B) Transitions
between the different arms of the maze was used as an index of locomotor activity. Mean ±
SEM, n= 6–8 rats. *p<0.05, significant behavioral effect of CP55940 compared with their
respective vehicle-treated control rats.
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